Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H12N2O3 |
Molecular Weight | 232.2353 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
InChI
InChIKey=DDBREPKUVSBGFI-UHFFFAOYSA-N
InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
Molecular Formula | C12H12N2O3 |
Molecular Weight | 232.2353 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/monograph/phenobarbital.htmlCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01174
Sources: https://www.drugs.com/monograph/phenobarbital.html
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01174
Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16981722 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LUMINAL Approved UseShort-term treatment of insomnia. However, generally not used orally as a hypnotic because several hours are required to achieve maximal effectsa and barbiturates have decreased effectiveness for sleep induction and maintenance after 2 weeks. |
|||
Primary | LUMINAL Approved UseRelief of anxiety, tension, and apprehension. However, barbiturates used infrequently for routine sedation, since there are few clinical situations in which oral barbiturates provide a safety or efficacy advantage over nonbarbiturate sedatives/hypnotics. |
|||
Primary | LUMINAL Approved UseManagement of tonic-clonic seizures and partial seizures; used alone (particularly in infants and young children) or, more commonly, in combination with phenytoin or other anticonvulsants. |
|||
Preventing | LUMINAL Approved UsePrevention of febrile seizures in infants and young children. |
|||
Primary | LUMINAL Approved UseSecond-line agent in the termination of status epilepticus; may be useful to prevent seizure recurrence after seizures are initially terminated with other anticonvulsants (e.g., diazepam, phenytoin) or for termination of status epilepticus that does not respond to initial therapy with other anticonvulsants. Usefulness of parenteral phenobarbital in terminating acute seizure episodes is limited by its slow onset of action |
|||
Preventing | LUMINAL Approved UseProphylactic management of epilepsy. |
|||
Primary | LUMINAL Approved UsePrevention and treatment of hyperbilirubinemia in neonates |
|||
Primary | LUMINAL Approved UseHas been used to reduce bilirubin concentrations in patients with congenital nonhemolytic unconjugated hyperbilirubinemia or chronic intrahepatic cholestasis. Has been used in the management of hyperlipemia associated with intrahepatic and extrahepatic cholestasis |
PubMed
Title | Date | PubMed |
---|---|---|
Enhancement of GABAergic inhibition: a mechanism of action of benzodiazepines, phenobarbital, valproate and L-cycloserine in the cat spinal cord. | 1982 |
|
General anaesthetic actions on ligand-gated ion channels. | 1999 Aug 15 |
|
On the mechanism of alleviation by phenobarbital of the malfunction of an epilepsy-linked GABA(A) receptor. | 2006 Sep 26 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/monograph/phenobarbital.html
Phenobarbital is administered orally or by IM or slow IV injection. For treatment of anxiety, phenobarbital is administered orally 6 mg/kg daily or 180 mg/m2 daily, in 3 equally divided doses. For treatment of seizure disorders, the drug is administered orally 15–50 mg 2 or 3 times daily. Alternatively, 3–5 mg/kg or 125 mg/m2 daily; IV or IM 4–6 mg/kg daily for 7–10 days to reach therapeutic blood concentrations; alternatively, 10–15 mg/kg daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16981722
Potentiation of the GABAA by phenobarbital was evaluated in HEK293 cells expressing recombinant rat GABAA receptors. Currents were recorded using the cell-flow technique and corrected for receptor desensitization. Co-application of phenobarbital with 300uM GABA lead to 20-30 amplification of chloride currents with EC50 of 100-200 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:27:44 GMT 2023
by
admin
on
Fri Dec 15 16:27:44 GMT 2023
|
Record UNII |
YQE403BP4D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN03AA02
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
CFR |
21 CFR 1308.22
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
WHO-ATC |
N03AA02
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
05
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
EPA PESTICIDE CODE |
600122
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
FDA ORPHAN DRUG |
725519
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
FDA ORPHAN DRUG |
703819
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
FDA ORPHAN DRUG |
601717
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
LIVERTOX |
NBK548269
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
IARC | Phenobarbital | ||
|
DEA NO. |
2285
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
||
|
CFR |
21 CFR 862.3660
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2804
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
2134
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
C739
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
PHENOBARBITAL
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
1524001
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
200-007-0
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
PHENOBARBITAL
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless. Solubility: Soluble in about 1100 parts of water, in about 10 parts of ethanol (~750 g/l) TS and in about 15 parts of ether R. Category: Hypnotic; sedative; anticonvulsant. Storage: Phenobarbital should be kept in a well-closed container. Additional information: Phenobarbital may exhibit polymorphism. Definition: Phenobarbital contains not less than 98.0% and not more than 101.0% of C12H12N2O3, calculated with reference tothe dried substance. | ||
|
100000090330
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
8069
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
YQE403BP4D
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
Phenobarbital
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
DTXSID5021122
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
m8622
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
28918
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
9848
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
D010634
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
3157
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL40
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
YQE403BP4D
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
DB01174
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
4763
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
SUB09770MIG
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
128143
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
50-06-6
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | |||
|
8134
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY | RxNorm | ||
|
414
Created by
admin on Fri Dec 15 16:27:44 GMT 2023 , Edited by admin on Fri Dec 15 16:27:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INDUCER | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
LABELED -> NON-LABELED |
|
||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> INDUCER | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
||
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC PHARMACOKINETIC PHARMACOKINETIC |
|
||